Domino’s Pizza Trades at Just 20.1x Times Earnings — Its Lowest Valuation in Nearly a Decade. There’s Only 2 Explanations for Why Domino’s Is This Cheap.
Domino’s (DPZ -3.13%) at roughly 20 times earnings is not just a little cheaper than usual. Domino’s is trading more than a third below its typical valuation over the past decade, a level the stock rarely touched even during pizza fatigue or delivery wars.
There are really only two explanations for why a brand this strong is suddenly this cheap. First, investors are scared that the GLP‑1 weight loss drug boom and sluggish traffic mean the Domino’s growth story might be structurally broken. Last year, analysts even marked the ticker as a sell due to the rising popularity of weight loss drugs.
Image source: Getty Images.
Same-store sales are plateauing
Over the last year, Domino’s results have looked fine at the top line but tired underneath. Revenue is still growing in the low single digits, and the company continues to add stores, with about 180 net openings in Q1 and more than 200 in Q2, pushing the global footprint above 22,000 locations.
Yet U.S. same-store sales have barely moved, up 0.9% in Q1 and just 0.1% in Q2, and international comps have drifted slightly negative once you strip out foreign exchange. On paper, that is still growth. In sentiment, it looks like a chain that is working harder for not much more pizza.
Today’s Change
(-3.13%) $-10.85
Current Price
$335.42
Key Data Points
Market Cap
Day’s Range
$334.49 – $345.00
52wk Range
$282.00 – $469.00
Volume
72
Avg Vol
895.1K
Gross Margin
40.02%
Dividend Yield
2.22%
Weight loss drugs might be impacting sales
Layer on the GLP‑1 story, and you can see why the market is jumpy. Analysts now expect tens of millions of Americans to be on drugs like Wegovy and Zepbound by 2030, with studies already showing real drops in calorie intake, sugar, and processed carbs. Restaurant data suggests GLP‑1 users eat out less, especially for high-calorie categories, and forecast models call for tens of billions of dollars of food and beverage sales to disappear as adoption rises.
Domino’s CEO has said the chain has not yet seen a measurable GLP‑1 impact, but markets are forward-looking and are starting to price in the possibility that “late-night pizza because I feel like it” becomes a smaller habit.
Put these two things together, and the current valuation makes more emotional sense. Investors are not doubting Domino’s ability to run a franchise system or manage costs. They are questioning whether the category can still deliver the kind of steady mid-single-digit comp growth that once supported a 30x earnings multiple.
If you believe GLP‑1 adoption and health habits will cap how much pizza people eat, a lower multiple feels rational. If you believe Domino’s will adapt with value offers, menu tweaks, and global expansion while GLP‑1 impact stays modest, then today’s pricing looks more like a fear discount on a still-powerful brand.
